Capecitabine treatment results in increased mean corpuscular volume of red blood cells in patients with advanced solid malignancies

Anti-Cancer Drugs

Volumn 14, Issue 2, 2003, Pages 119-123

  Wenzel, Catharina ^a   Mader, Robert M ^a   Steger, Guenther G ^a   Pluschnig, Ursula ^a   Kornek, Gabriela V ^a   Scheithauer, Werner ^a   Locker, Gottfried J ^a,b  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

5 Fluorouracil; Capecitabine; Erythrocyte mean corpuscular volume; Thymidylate synthase

Indexed keywords

ALPHA INTERFERON; CAPECITABINE; CYANOCOBALAMIN; FLUOROURACIL; FOLIC ACID; GAMMA INTERFERON; GEMCITABINE; HOMOCYSTEINE; OXALIPLATIN; RECOMBINANT INTERLEUKIN 2;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD CELL COUNT; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER STAGING; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ERYTHROCYTE VOLUME; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; MONOTHERAPY; PANCREAS CANCER; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; ERYTHROCYTE INDICES; ERYTHROCYTES; FEMALE; FOLIC ACID; HEMATINICS; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; THYMIDYLATE SYNTHASE; VITAMIN B 12;

EID: 0037331579     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200302000-00005     Document Type: Article

References (24)

1. Meta-Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998; 16:3537-3541.
2. Comella P, Crucitta E, De Vita F, De Lucia L, Farris A, Del Gaizo F, et al. Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomized study by the Southern Italy Cooperative Oncology Group. Ann Oncol 2002; 13:866-873.
3. Mani S, Vogelzang NJ, Bertucci D, Stadler WM, Schilsky RL, Ratain MJ. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. Cancer 2001; 92:1567-1576.
4. Cocconi G, Blasio BD, Boni C, Bisagni G, Ceci G, Rondini E, et al. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma. Cancer 2002; 95:228-235.
5. Van Triest B, Pinedo HM, Blaauwgeers LG, Van Diest PJ, Schoenmakers P, Telleman F, et al. Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res 2000; 6:1063-1072.
6. Peters GJ, Jansen G. Resistance to antimetabolites. In: Schilsky RL, Milano GA, Ratain MJ (editors): Principles of Antineoplastic Drug Development and Pharmacology. New York: Marcel Dekker; 1996, pp. 543-585.
7. Takebayashi Y, Akiyama S, Akiba S, Yamada K, Miyadera K, Sumizawa T, et al. Clinicopathologic and prognostic significance of an angiogenetic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 1996; 88:1110-1117.
8. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34:1274-1281.
9. 4-pentoxycarbonyl-5′-deoxy-5-fluorocytidine (capecitabine). Biol Pharm Bull 1998; 21:713-717.
10. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998; 58:685-690.
11. Twelves C. Vision of the future: capecitabine. Oncologist 2001; 6:35-39.
12. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20:2812-2823.
13. Diaz-Rubio E, Evans TR, Tabemero J, Cassidy J, Sastre J, Eatock M, et al. Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors. Ann Oncol 2002; 13:558-565.
14. Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, et al. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002; 20:1759-1766.
15. Wenzel C, Locker GJ, Schmidinger M, Mader R, Kramer G, Marberger M, et al. Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy. Am J Kidney Dis 2002; 39:48-54.
16. Schmidinger M, Steger GG, Wenzel C, Locker GJ, Brodowicz T, Budinsky AC, et al. Sequential administration of interferon gamma and interleukin-2 in metastatic renal cell carcinoma: results of a phase II trial: Austrian Renal Cell Carcinoma Study Group. Cancer Immunol Immunother 2000; 49:395-400.
17. Oevermann K, Buer J, Hoffmann R, Franzke A, Schrader A, Patzelt T, et al. Capecitabine in the treatment of metastatic renal cell carcinoma. Br J Cancer 2000; 83:583-587.
18. Nichols CR, Akard LP. Hematologic problems in patients with cancer and chronic inflammatory disorders. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ (editors): Hematology. Basic Principles and Practice. New York: Churchill Livingstone; 1991, pp. 1733-1746.
19. Berliner N, Duffy PD. Approach to the patient with anemia. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ (editors): Hematology. Basic Principles and Practice. New York: Churchill Livingstone; 1991, pp. 302-319.
20. Hoffbrand AV, Waters AH. Observations on the biochemical basis of megaloblastic anaemia. Br J Haematol 1972; 23:109-118.
21. Spears CP, Gustavsson BG, Frosing R. Folinic acid modulation of fluorouracil: tissue kinetics of bolus administration. Invest New Drugs 1989; 7:27-36.
22. 19F nuclear magnetic resonance spectroscopy pharmacokinetics. J Clin Oncol 1990; 8:1868-1873.
23. Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, et al. Preferential activation of capecitabine in tumor following oral administration to cotorectal cancer patients. Cancer Chemother Pharmacol 2000; 45:291-297.
24. Allegra C. Thymidylate synthase levels: prognostic, predictive, or both? J Clin Oncol 2002; 20:1711-1713.